DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Carmen Hidalgo-Tenorio,Juan Pasquau,David Vinuesa,Sergio Ferra,Alberto Terron,Isabel SanJoaquin,Antoni Payeras,Onofre Juan Martinez,Miguel Angel Lopez-Ruz,Mohamed Omar,Javier de la Torre-Lima,Ana Lopez-Lirola,Jesus Palomares,Jose Ramon Blanco,Marta Montero,Coral Garcia-Vallecillos Viruses（2022）
关键词
DOLAVI,dolutegravir,lamivudine,real-world data,HIV
AI 理解论文
溯源树
样例
